Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
- PMID: 7579495
- DOI: 10.1007/BF00665976
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
Abstract
One hundred and twelve post menopausal or post oophorectomy women with advanced breast cancer (BC) who had all previously had aminoglutethimide (AG) were treated with the potent aromatase inhibitor 4-hydroxy androstenedione (4-OHA). Twenty three women (21%) had a partial response to 4-OHA while another twenty five patients (22%) had stabilization of previously progressing disease. Patients responded to 4-OHA both after previously responding to then relapsing on, and after failing to respond to aminoglutethimide. Toxicity was minimal. This study shows that potent aromatase inhibition with 4-OHA is effective in women with advanced BC who have already been treated with a less potent aromatase inhibitor, and suggests that relative changes in oestrogen levels may be more important than absolute levels.
Similar articles
-
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.Br J Cancer. 1994 Jun;69(6):1171-5. doi: 10.1038/bjc.1994.230. Br J Cancer. 1994. PMID: 8198987 Free PMC article.
-
Treatment of advanced breast cancer with formestane.Ann Oncol. 1994;5 Suppl 7:S11-3. Ann Oncol. 1994. PMID: 7873455
-
Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.J Int Med Res. 1992 Aug;20(4):303-12. doi: 10.1177/030006059202000401. J Int Med Res. 1992. PMID: 1387368 Review.
-
Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.Eur J Cancer. 1996 May;32A(5):789-92. doi: 10.1016/0959-8049(95)00623-0. Eur J Cancer. 1996. PMID: 9081355 Clinical Trial.
-
Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):155-9. doi: 10.1016/0960-0760(92)90201-s. J Steroid Biochem Mol Biol. 1992. PMID: 1388047 Review.
Cited by
-
Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.Drug Saf. 1999 Oct;21(4):297-309. doi: 10.2165/00002018-199921040-00005. Drug Saf. 1999. PMID: 10514021 Review.
-
Estrogen receptor alpha in human breast cancer: occurrence and significance.J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):271-81. doi: 10.1023/a:1009594727358. J Mammary Gland Biol Neoplasia. 2000. PMID: 14973389 Review.
-
Is there a growing role for endocrine therapy in the treatment of breast cancer?Drugs. 2000 Jul;60(1):11-21. doi: 10.2165/00003495-200060010-00002. Drugs. 2000. PMID: 10929927 Review.
-
Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.Drugs Aging. 1996 Oct;9(4):292-306. doi: 10.2165/00002512-199609040-00006. Drugs Aging. 1996. PMID: 8894526 Review.
-
Understanding the mechanisms of aromatase inhibitor resistance.Breast Cancer Res. 2012 Jan 19;14(1):201. doi: 10.1186/bcr2931. Breast Cancer Res. 2012. PMID: 22277572 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical